1.Interpretation of updated NCCN clinical practice guidelines for lung cancer screening (version 2. 2022)
Haojie SI ; Long XU ; Fang WANG ; Hang SU ; Yunlang SHE ; Chenyang DAI ; Xuefei HU ; Deping ZHAO ; Yuming ZHU ; Peng ZHANG ; Gening JIANG ; Chang CHEN
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2022;29(11):1407-1413
Lung cancer is the most common cancer and the leading cause of cancer-related death in China. Early screening of lung cancer proves to be effective in improving its prognosis. The National Comprehensive Cancer Network (NCCN) has updated and released version 2, 2022 NCCN clinical practice guidelines for lung cancer screening in July, 2022. Based on high-quality clinical evidence and the latest research progress, the guidelines have developed and updated criteria for lung cancer screening which have been widely recognized by clinicians around the world. Compared with Chinese lung cancer screening guidelines, this article will interpret the updated content of the brand new 2022 NCCN screening guidelines, providing some reference for the current lung cancer screening practice in our country.
Result Analysis
Print
Save
E-mail